UBS Group’s Scinai Immunotherapeutics SCNI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $524 | Sell |
919
-829
| -47% | -$668 | ﹤0.01% | 9849 |
|
|
2025
Q4 | $1.25K | Buy |
1,748
+1,740
| +21,750% | +$1.98K | ﹤0.01% | 9652 |
|
|
2025
Q3 | $10 | Sell |
8
-12,048
| -100% | -$21K | ﹤0.01% | 10189 |
|
|
2025
Q2 | $27.5K | Sell |
12,056
-2,876
| -19% | -$7.24K | ﹤0.01% | 8223 |
|
|
2025
Q1 | $40.2K | Sell |
14,932
-8,556
| -36% | -$29.3K | ﹤0.01% | 7743 |
|
|
2024
Q4 | $78.6K | Buy |
23,488
+23,458
| +78,193% | +$80.6K | ﹤0.01% | 7024 |
|
|
2024
Q3 | $104 | Sell |
30
-181
| -86% | -$692 | ﹤0.01% | 9156 |
|
|
2024
Q2 | $586 | Sell |
211
-1
| -0.5% | -$4 | ﹤0.01% | 8854 |
|
|
2024
Q1 | $1.1K | Hold |
212
| – | – | ﹤0.01% | 8231 |
|
|
2023
Q4 | $1.26K | Buy |
212
+130
| +159% | +$894 | ﹤0.01% | 8359 |
|
|
2023
Q3 | $717 | Buy |
82
+51
| +165% | +$654 | ﹤0.01% | 8314 |
|
|
2023
Q2 | $431 | Sell |
31
-501
| -94% | -$8.65K | ﹤0.01% | 8238 |
|
|
2023
Q1 | $11.5K | Buy |
532
+502
| +1,673% | +$12.4K | ﹤0.01% | 7499 |
|
|
2022
Q4 | $888 | Sell |
30
-50
| -63% | -$3.76K | ﹤0.01% | 10044 |
|
|
2022
Q3 | $6K | Buy |
80
+33
| +70% | +$3.71K | ﹤0.01% | 9058 |
|
|
2022
Q2 | $5K | Sell |
47
-56
| -54% | -$7.69K | ﹤0.01% | 8927 |
|
|
2022
Q1 | $17K | Buy |
103
+31
| +43% | +$4.5K | ﹤0.01% | 7666 |
|
|
2021
Q4 | $16K | Buy |
72
+45
| +167% | +$9.29K | ﹤0.01% | 8178 |
|
|
2021
Q3 | $6K | Buy |
27
+11
| +69% | +$2.82K | ﹤0.01% | 8441 |
|
|
2021
Q2 | $5K | Buy |
+16
| New | +$4.98K | ﹤0.01% | 8565 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 9408 |
|
|
2020
Q3 | – | Sell |
-19
| Closed | -$43K | – | 8358 |
|
|
2020
Q2 | $43K | Buy |
+19
| New | +$30.6K | ﹤0.01% | 5987 |
|
|
2019
Q2 | – | Sell |
-9
| Closed | -$5K | – | 8117 |
|
|
2019
Q1 | $5K | Sell |
9
-21
| -70% | -$10.9K | ﹤0.01% | 7178 |
|
|
2018
Q4 | $14K | Sell |
30
-16
| -35% | -$8.63K | ﹤0.01% | 7049 |
|
|
2018
Q3 | $25K | Buy |
46
+33
| +254% | +$19.7K | ﹤0.01% | 6672 |
|
|
2018
Q2 | $8K | Sell |
13
-8
| -38% | -$5.18K | ﹤0.01% | 7269 |
|
|
2018
Q1 | $11K | Buy |
+21
| New | +$13.1K | ﹤0.01% | 6815 |
|
|
2016
Q4 | – | Sell |
-1
| Closed | – | – | 8001 |
|
|
2016
Q3 | $0 | Sell |
1
-13
| -93% | -$4.73K | ﹤0.01% | 7893 |
|
|
2016
Q2 | $5K | Buy |
+14
| New | +$5.17K | ﹤0.01% | 7133 |
|
|
2015
Q4 | – | Sell |
-35
| Closed | -$13K | – | 8540 |
|
|
2015
Q3 | $13K | Buy |
35
+9
| +35% | +$3.68K | ﹤0.01% | 7084 |
|
|
2015
Q2 | $13K | Buy |
+26
| New | +$12.2K | ﹤0.01% | 7266 |
|
Other funds holding SCNI
UBS Group's SCNI Position: Q1 2026 in Review
UBS Group reduced its Scinai Immunotherapeutics (SCNI) stake by 47% in Q1 2026, selling an estimated $668 and leaving 919 shares worth $524. The position accounts for ﹤0.01% of the portfolio, ranked #9849.
UBS Group first reported a position in SCNI in Q2 2015 and has held it in 30 quarters since. The position peaked at $78.6K in Q4 2024. 4 funds tracked by Wall St. Rank hold SCNI as of Q1 2026.
- UBS Group held 919 shares of Scinai Immunotherapeutics worth $524 as of Q1 2026.
- UBS Group sold 829 Scinai Immunotherapeutics shares in Q1 2026, an estimated $668.
- Scinai Immunotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9849 holding.
- UBS Group first reported a position in Scinai Immunotherapeutics in Q2 2015 and has held it in 30 quarters since.
- UBS Group's Scinai Immunotherapeutics position peaked at $78.6K in Q4 2024.
- 4 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.